These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 30568177)

  • 61. Targeting DNA repair and replication stress in the treatment of ovarian cancer.
    Murai J
    Int J Clin Oncol; 2017 Aug; 22(4):619-628. PubMed ID: 28643177
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer.
    Tewari KS; Eskander RN; Monk BJ
    Clin Cancer Res; 2015 Sep; 21(17):3829-35. PubMed ID: 26169965
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.
    Lheureux S; Lai Z; Dougherty BA; Runswick S; Hodgson DR; Timms KM; Lanchbury JS; Kaye S; Gourley C; Bowtell D; Kohn EC; Scott C; Matulonis U; Panzarella T; Karakasis K; Burnier JV; Gilks CB; O'Connor MJ; Robertson JD; Ledermann J; Barrett JC; Ho TW; Oza AM
    Clin Cancer Res; 2017 Aug; 23(15):4086-4094. PubMed ID: 28223274
    [No Abstract]   [Full Text] [Related]  

  • 64. Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil.
    Maistro S; Teixeira N; Encinas G; Katayama ML; Niewiadonski VD; Cabral LG; Ribeiro RM; Gaburo Junior N; de Gouvêa AC; Carraro DM; Sabino EC; Diz MD; Chammas R; de Bock GH; Folgueira MA
    BMC Cancer; 2016 Dec; 16(1):934. PubMed ID: 27914478
    [TBL] [Abstract][Full Text] [Related]  

  • 65. PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.
    Geenen JJJ; Linn SC; Beijnen JH; Schellens JHM
    Clin Pharmacokinet; 2018 Apr; 57(4):427-437. PubMed ID: 29063517
    [TBL] [Abstract][Full Text] [Related]  

  • 66. EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
    Yamaguchi H; Du Y; Nakai K; Ding M; Chang SS; Hsu JL; Yao J; Wei Y; Nie L; Jiao S; Chang WC; Chen CH; Yu Y; Hortobagyi GN; Hung MC
    Oncogene; 2018 Jan; 37(2):208-217. PubMed ID: 28925391
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors.
    Mukhopadhyay A; Elattar A; Cerbinskaite A; Wilkinson SJ; Drew Y; Kyle S; Los G; Hostomsky Z; Edmondson RJ; Curtin NJ
    Clin Cancer Res; 2010 Apr; 16(8):2344-51. PubMed ID: 20371688
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum].
    Škapa P; Dundr P
    Cesk Patol; 2016; 52(4):199-204. PubMed ID: 27869446
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review.
    Arts-de Jong M; de Bock GH; van Asperen CJ; Mourits MJ; de Hullu JA; Kets CM
    Eur J Cancer; 2016 Jul; 61():137-45. PubMed ID: 27209246
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE; Kennedy RD
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [TBL] [Abstract][Full Text] [Related]  

  • 71. BRCA Mutation Status to Personalize Management of Recurrent Ovarian Cancer: A Multicenter Study.
    Marchetti C; De Leo R; Musella A; D'Indinosante M; Capoluongo E; Minucci A; Benedetti Panici P; Scambia G; Fagotti A
    Ann Surg Oncol; 2018 Nov; 25(12):3701-3708. PubMed ID: 30128899
    [TBL] [Abstract][Full Text] [Related]  

  • 72. DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.
    Dhawan M; Ryan CJ; Ashworth A
    Oncologist; 2016 Aug; 21(8):940-5. PubMed ID: 27317574
    [TBL] [Abstract][Full Text] [Related]  

  • 73. PARP inhibitors plough on.
    Mullard A
    Nat Rev Drug Discov; 2017 Mar; 16(4):229. PubMed ID: 28356598
    [No Abstract]   [Full Text] [Related]  

  • 74. Ratio-Dependent Synergism of a Doxorubicin and Olaparib Combination in 2D and Spheroid Models of Ovarian Cancer.
    Eetezadi S; Evans JC; Shen YT; De Souza R; Piquette-Miller M; Allen C
    Mol Pharm; 2018 Feb; 15(2):472-485. PubMed ID: 29283581
    [TBL] [Abstract][Full Text] [Related]  

  • 75. BRCAness revisited.
    Lord CJ; Ashworth A
    Nat Rev Cancer; 2016 Feb; 16(2):110-20. PubMed ID: 26775620
    [TBL] [Abstract][Full Text] [Related]  

  • 76. CT prediction of surgical outcome in patients with advanced epithelial ovarian carcinoma undergoing neoadjuvant chemotherapy.
    Bregar A; Mojtahed A; Kilcoyne A; Kurra V; Melamed A; Growdon W; Alejandro Rauh-Hain J; Del Carmen M; Lee SI
    Gynecol Oncol; 2019 Mar; 152(3):568-573. PubMed ID: 30642626
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Evaluation of the methods to identify patients who may benefit from PARP inhibitor use.
    Lim D; Ngeow J
    Endocr Relat Cancer; 2016 Jun; 23(6):R267-85. PubMed ID: 27226207
    [TBL] [Abstract][Full Text] [Related]  

  • 78. BRCA1/2 germline testing in non-mucinous epithelial ovarian carcinoma: changing international practice and implications for service provision.
    Coakley M; Cleary V; Power N; O'Reilly S
    Eur J Hum Genet; 2017 Feb; 25(2):167-168. PubMed ID: 27759028
    [No Abstract]   [Full Text] [Related]  

  • 79. Comprehensive BRCA1 and BRCA2 mutational profile in Lithuania.
    Janavičius R; Rudaitis V; Mickys U; Elsakov P; Griškevičius L
    Cancer Genet; 2014 May; 207(5):195-205. PubMed ID: 25066507
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Recommendations for biomarker testing in epithelial ovarian cancer. A national consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology].
    Oaknin A; Guarch R; Barretina P; Hardisson D; González-Martín A; Matías-Guiu X; Pérez-Fidalgo A; Vieites B; Romero I; Palacios J
    Rev Esp Patol; 2018; 51(2):84-96. PubMed ID: 29602379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.